Midatech Pharma PLC Result of 2022 Annual General Meeting (5177P)

TIDMMTPH

RNS Number : 5177P

Midatech Pharma PLC

20 June 2022

20 June 2022

Midatech Pharma PLC

("Midatech" or the "Company")

Result of 2022 Annual General Meeting

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its Annual General Meeting (AGM) held at 2.00pm today all resolutions put to the meeting were duly passed.

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: [phone] 
 www.midatechpharma.com 
 
 Strand Hanson Limited (Nominated and Financial Adviser) 
 James Dance / Matthew Chandler / Rob Patrick 
 Tel: [phone] 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker / James Pope 
  Tel: [phone] 
 
   IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: [phone] 
 Email: [e-mail] 
 
 Edison Group (US Investor Relations) 
 Alyssa Factor 
 Tel: [phone] 
 Email: [e-mail] 
 
 
           About Midatech Pharma PLC 
            Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
            MTP) is a drug delivery technology company focused on improving 
            the bio-delivery and bio-distribution of medicines . The Company 
            combines approved and development medications with its proprietary 
            and innovative drug delivery technologies, to provide compelling 
            products that have the potential to powerfully impact the lives 
            of patients. 
 
            The Company has developed three in-house technology platforms, 
            each with its own unique mechanism to improve delivery of medications 
            to sites of disease. All of the Company's technologies have successfully 
            entered human use in the clinic, providing important validation 
            of the potential for each platform: 
 
             *    Q-Sphera(TM) platform: a disruptive micro-technology 
                  used for sustained release to prolong and control the 
                  release of therapeutics over an extended period of 
                  time (from weeks to months). 
 
 
             *    MidaSolve(TM) platform: an innovative nanotechnology 
                  used to dissolve insoluble drugs so that they can be 
                  administered in liquid form directly and locally into 
                  tumours. 
 
 
             *    MidaCore(TM) platform: a leading-edge nanotechnology 
                  used for targeting medications to sites of disease. 
 
 
 
            The platform nature of the technologies offers the potential to 
            develop multiple drug assets rather than being reliant on a limited 
            number of programmes. Midatech's technologies are supported by 
            36 patent families including 120 granted patents and an additional 
            70 patent applications. Midatech's headquarters and R&D facility 
            is in Cardiff, UK. For more information, please visit www.midatechpharma.com 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBXGDLDXDDGDG

(END) Dow Jones Newswires

June 20, 2022 09:33 ET (13:33 GMT)